COLUMBUS, OHIO April 6, 2021 – Forge Biologics, a cGMP manufacturing and development company, announced today that Timothy J. Miller, […]
PRESS: Forge Biologics to Present at 2021 Virtual Cell and Gene Meeting on the Mediterranean
Forge Biologics
Hearthside Chat Video Series
We are excited to unveil our Hearthside Chat series – our version of a fireside chat – from our home […]
PRESS: FDA Fast Track, ODD, and RPDD Designations for FBX-101 Gene Therapy for Patients with Krabbe Disease
The FDA has granted Fast Track Designation, Rare Pediatric Disease Designation, and Orphan Drug Designation to FBX-101 for treatment of patients […]
PRESS: United Leukodystrophy Foundation
We’re pleased to share that the United Leukodystrophy Foundation has shared our press release, marking yet another avenue of informing […]
VIDEO: Manufacturing Capabilities
We are passionate about serving our clients by providing the highest quality vector and leading the industry in technological advancements. […]
“Building Better” Blog: Forge Biologics Spotlight
We are thrilled to have a spotlight in National Venture Capital Association‘s (NVCA) Building Better blog series alongside Molly (McCartin) Bonakdarpour of Drive […]
RESKUE Trial for Patients with Krabbe Disease
With new beginnings comes new hope. As we enter 2021, screening will begin for the our Phase 1/2 RESKUE trial […]
Announcing: Blaze Vector™ Production
As we begin 2021, we’d like to introduce you to our new Blaze Vector™ AAV production line. Utilizing our proprietary […]
PRESS: FDA Clearance of Investigational New Drug for Patients with Krabbe Disease
Forge Biologics has received IND, IBC, and IRB clearance for FBX-101, a gene therapy for patients with Krabbe disease, a […]
Our Gene Therapy Players: The Starting Lineup
In the spirit of football season, we’re introducing our very own roster of seasoned #genetherapy players. Our leadership team has […]